Steinhoff International Holdings N.V.

  • WKN: A14XB9
  • ISIN: NL0011375019
  • Land: Niederlande

Nachricht vom 18.10.2021 | 09:10


DGAP-News: Steinhoff International Holdings N.V. / Key word(s): Over Indebtedness
18.10.2021 / 09:10
The issuer is solely responsible for the content of this announcement.


Steinhoff International Holdings N.V. ("SIHNV" or the "Company" and together with its subsidiaries, "Steinhoff") together with Steinhoff International Holdings Proprietary Limited ("SIHPL") provide the following update with respect to the Steinhoff global litigation settlement proposal.

On 11 August 2021 the Company announced an increased offer and stated that:

"Following this announcement, SIHNV and SIHPL will proceed to seek further approval from the South Africa Reserve Bank/FINSURV for necessary approvals."

Steinhoff is pleased to announce that it has received approval from SARB/FINSURV for the cross-border transfers contemplated by the revised Steinhoff global settlement proposal. The approval is valid until 31 May 2022.

Louis du Preez, Chief Executive Officer, said:

"The FINSURV approval satisfies one of the remaining conditions to implementation of the global litigation settlement. The final material requirement is the approval of the High Court in South Africa to the SIHPL section 155 proposal. Given the overwhelming claimant support in favour of the settlement proposal, we are committed to implementing it as soon as possible."

The Company has a primary listing on the Frankfurt Stock Exchange and a secondary listing on the JSE Limited.

Stellenbosch, South Africa

18 October 2021

18.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021